Stock Splits
By The Online Investor Staff, updated Sat., Apr. 27, 6:10 AM
| This Slide: #8 of 25 |
Slide #8. Windtree Therapeutics, Inc. (NASDAQ:WINT) — 1 for 18 Reverse Split
Announced:
4/18/2024
Stock Split:
1 for 18
Record Date:
4/19/2024
Pay Date:
4/22/2024
WINT Optionable?:
No
Windtree Therapeutics is a biopharmaceutical company focused on the development of therapeutics. Co.'s primary product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure. Co.'s heart failure cardiovascular portfolio also includes sarco endoplasmic reticulum Ca2+ -ATPase 2a (SERCA2a) activators. This research program is evaluating these preclinical product candidates, including oral and intravenous SERCA2a activator heart failure compounds. In addition, Co.'s cardiovascular drug product candidates include rostafuroxin, a product candidate for the treatment of hypertension in patients with a specific genetic profile. 
WINT Detailed Information Page & Split History »
|
|||||||||||||||||||||
Open the WINT Page at The Online Investor (in a new window) »
 Free WINT Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (3.00 out of 4) 23rd percentile
(ranked lower than approx. 77% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
